![1 Sec. 69/21/11 If you click on the red arrow, you will skip to a view of Teva's stock chart. - ppt download 1 Sec. 69/21/11 If you click on the red arrow, you will skip to a view of Teva's stock chart. - ppt download](https://images.slideplayer.com/15/4852943/slides/slide_3.jpg)
1 Sec. 69/21/11 If you click on the red arrow, you will skip to a view of Teva's stock chart. - ppt download
![ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business](https://mms.businesswire.com/media/20180914005613/en/678526/5/AJOVY+Image.jpg)
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
![TEVA PHARMACEUTICALS By: Kaity Brown. About Teva Established in Became TEVA pharmaceuticals in the 1930s Currently their headquarters is in. - ppt download TEVA PHARMACEUTICALS By: Kaity Brown. About Teva Established in Became TEVA pharmaceuticals in the 1930s Currently their headquarters is in. - ppt download](https://images.slideplayer.com/22/6345323/slides/slide_2.jpg)
TEVA PHARMACEUTICALS By: Kaity Brown. About Teva Established in Became TEVA pharmaceuticals in the 1930s Currently their headquarters is in. - ppt download
![Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire](https://mms.businesswire.com/media/20210831005107/en/739014/22/teva_RGB_JPEG.jpg)
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire
![The ALS Association, Huntington's Disease Society of America, and Teva Pharmaceuticals Launch Teva CNS Target Identification Challenge - The ALS Association The ALS Association, Huntington's Disease Society of America, and Teva Pharmaceuticals Launch Teva CNS Target Identification Challenge - The ALS Association](https://secure2.convio.net/alsa/images/content/pagebuilder/blog-031218-image.png)